GYN 4: phase I study of BIBF 1120 in combination with paclitaxel/carboplatin in patients with advanced gynecological malignancies

被引：0
|
作者：
Huober, J. [1 ]
Pfisterer, J. [2 ]
Wimberger, P. [3 ]
Loibl, S. [4 ]
Stopfer, P. [5 ]
du Bois, A. [6 ]
机构：
[1] Kantonsspital St Gallen, Senolog Zentrum, St Gallen, Switzerland
[2] Univ Klinikum Schleswig Holstein, Kiel, Germany
[3] Univ Frauenklin, Essen, Germany
[4] Univ Frauenklin Frankfurt Main, Frankfurt, Germany
[5] Boehringer Ingelheim Pharm GmbH & Co, Biberach, Germany
[6] Klin Gynakol & Gynakol Onkol, Dr Horst Schmidt Klin GmbH, HSK, Wiesbaden, Germany
来源：
GEBURTSHILFE UND FRAUENHEILKUNDE | 2008年 / 68卷
关键词：
D O I：
暂无
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
引用
收藏
页码：S11 / S11
页数：1
相关论文
共 50 条
  • [31] Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results
    Heath, Elisabeth I.
    Blumenschein, George R., Jr.
    Cohen, Roger B.
    LoRusso, Patricia M.
    LoConte, Noelle K.
    Kim, Sindy T.
    Ruiz-Garcia, Ana
    Chao, Richard C.
    Wilding, George
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 68 (03) : 703 - 712
  • [32] A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade™), in combination with paclitaxel and carboplatin in patients with advanced malignancies
    Ma, Cynthia
    Mandrekar, Sumithra J.
    Alberts, Steven R.
    Croghan, Gary A.
    Jatoi, Aminah
    Reid, Joel M.
    Hanson, Lorelei J.
    Bruzek, Laura
    Tan, Angelina D.
    Pitot, Henry C.
    Erlichman, Charles
    Wright, John J.
    Adjei, Alex A.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2007, 59 (02) : 207 - 215
  • [33] A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade™), in combination with paclitaxel and carboplatin in patients with advanced malignancies
    Cynthia Ma
    Sumithra J. Mandrekar
    Steven R. Alberts
    Gary A. Croghan
    Aminah Jatoi
    Joel M. Reid
    Lorelei J. Hanson
    Laura Bruzek
    Angelina D. Tan
    Henry C. Pitot
    Charles Erlichman
    John J. Wright
    Alex A. Adjei
    Cancer Chemotherapy and Pharmacology, 2007, 59 : 207 - 215
  • [34] A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer
    Doebele, R. C.
    Conkling, P.
    Traynor, A. M.
    Otterson, G. A.
    Zhao, Y.
    Wind, S.
    Stopfer, P.
    Kaiser, R.
    Camidge, D. R.
    ANNALS OF ONCOLOGY, 2012, 23 (08) : 2094 - 2102
  • [35] Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignancies
    Bhatty, Minny
    Kato, Shumei
    Piha-Paul, Sarina A.
    Naing, Aung
    Subbiah, Vivek
    Huang, Helen J.
    Karp, Daniel D.
    Tsimberidou, Apostolia M.
    Zinner, Ralph G.
    Hwu, Wen-Jen
    Javle, Milind
    Patel, Sapna P.
    Hu, Mimi, I
    Varadhachary, Gauri R.
    Conley, Anthony P.
    Ramzanali, Nishma M.
    Holley, Veronica R.
    Kurzrock, Razelle
    Meric-Bernstam, Funda
    Chae, Young Kwang
    Kim, Kevin B.
    Falchook, Gerald S.
    Janku, Filip
    CANCER, 2019, 125 (03) : 463 - 472
  • [36] EARLY DATA FROM A PHASE I STUDY OF NINTEDANIB (BIBF 1120) IN ASIAN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA
    Yen, C.
    Shen, Y.
    Shiah, H.
    Chen, J.
    Hsu, C.
    Hsu, C.
    Huang, D. C.
    Hocke, J.
    Su, W.
    Cheng, A.
    ANNALS OF ONCOLOGY, 2012, 23 : 246 - 247
  • [37] Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies
    Villalona-Calero, MA
    Weiss, GR
    Burris, HA
    Kraynak, M
    Rodrigues, G
    Drengler, RL
    Eckhardt, SG
    Reigner, B
    Moczygemba, J
    Burger, HU
    Griffin, T
    Von Hoff, DD
    Rowinsky, EK
    JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (06) : 1915 - 1925
  • [38] Phase I study of vorinostat, a histone deacetylase (HDAC) inhibitor, in combination with carboplatin (Cb) and paclitaxel (P) for patients with advanced solid malignancies (NCI #6922).
    Ramalingam, S.
    Parise, R. A.
    Egorin, M. J.
    Argiris, A.
    Stoller, R.
    Beattie, L.
    Aparicio, A.
    Newman, E. M.
    Zwiebel, J.
    Belani, C. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 98S - 98S
  • [39] Phase I/II study of DHA-paclitaxel in combination with carboplatin in patients with advanced malignant solid tumours
    Harries, M
    O'Donnell, A
    Scurr, M
    Reade, S
    Cole, C
    Judson, I
    Greystoke, A
    Twelves, C
    Kaye, S
    BRITISH JOURNAL OF CANCER, 2004, 91 (09) : 1651 - 1655
  • [40] Mapatumumab, an Antibody Targeting TRAIL-R1, in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Malignancies: Results of a Phase I and Pharmacokinetic Study
    Leong, Stephen
    Cohen, Roger B.
    Gustafson, Daniel L.
    Langer, Corey J.
    Camidge, D. Ross
    Padavic, Kristin
    Gore, Lia
    Smith, Margaret
    Chow, Laura Q.
    von Mehren, Margaret
    O'Bryant, Cindy
    Hariharan, Sujatha
    Diab, Sami
    Fox, Norma Lynn
    Miceli, Renee
    Eckhardt, S. Gail
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (26) : 4413 - 4421
12345